Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...

Hims & Hers Health Inc.'s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

U.S. pharma companies should pay rather more of their corporate income tax in the U.S.—and start producing more of their best drugs in the U.S. as well.

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. | BrightGene ...

Hims & Hers Health shares tumbled 33% in intraday trading Monday after Novo Nordisk said it is pulling out of its partnership ...

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.

The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.

The report spotlights China’s rapid biopharma advancement, alongside a GLP-1 surge, caution surrounding M&A, and a rise in ...